Celldex Therapeutics Presents Positive Results From Phase 2 Study Of The Antibody-Dru [Archive]

View Full Version : Celldex Therapeutics Presents Positive Results From Phase 2 Study Of The Antibody-Dru

News

12-19-2009, 04:10 AM

Celldex Therapeutics, Inc. (NASDAQ: CLDX) announced the results of a positive Phase 2 study of CDX-011 (formerly CR011-vcMMAE), in patients with heavily pre-treated, locally advanced or metastatic breast cancers...

More... (http://www.medicalnewstoday.com/articles/173950.php)